Glaukos Presents Plans to Expand iDose Glaucoma Therapy Pipeline
Bitget2026/11/06 12:22- Glaukos launched Epioxa commercially in March 2026 as the first FDA-approved epithelium-on treatment for keratoconus.
- Revenue grew more than 30% in 2025, with a 10-year compound annual growth rate exceeding 20%.
- iDose TR received FDA approval for repeat administration in January 2026, supporting reuse of the long-duration glaucoma therapy.
- A new Phase 3 analysis showed iDose TR was noninferior to topical timolol at three years.
- The iDose pipeline includes TRIO in Phase 3b, with patient enrollment completed; TREX is advancing through a Phase 2b/3 program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
